Stocks · News reference

Incyte Says It's No Longer A One-Drug Story

Jul 28, 2026, 7:10 PMVandana Singh

Incyte (INCY) Q2 earnings beat estimates with $1.67B revenue, $3.09 EPS. Full-year sales guidance raised. Shares rally to new 52-week high.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 20, 2026, 7:44 PMBenzinga Newsdesk
Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152
Canaccord Genuity analyst John Newman initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $152.
Read original at benzinga
INCY
BenzingaAug 20, 2026, 11:41 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.
Read original at benzinga
INCY
BenzingaAug 17, 2026, 7:19 PMBenzinga Newsdesk
Incyte shares are trading higher after Piper Sandler maintained its Overweight rating on the stock and raised its price target from $110 to $130.
Read original at benzinga
INCY
BenzingaAug 17, 2026, 4:11 PMBenzinga Newsdesk
Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130
Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $110 to $130.
Read original at benzinga
INCY